Activation, regulation, and inhibition of DYRK1A

No abstract is available for this paper.

• Publication year

  2011

• Venue

  The FEBS Journal

• Publication date

  2011-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1742-4658.2010.07956.xPMID 21126318
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of DYRK1A in neurodegenerative diseases

  2011cited by this paper
• MNB/DYRK1A as a multiple regulator of neuronal development

  2011cited by this paper
• DYRK1A and Glycogen Synthase Kinase 3β, a Dual-Kinase Mechanism Directing Proteasomal Degradation of CRY2 for Circadian Timekeeping

  2010cited by this paper
• Characterization of a Domain That Transiently Converts Class 2 DYRKs into Intramolecular Tyrosine Kinases

  2010cited by this paper
• Direct Association of Sprouty-related Protein with an EVH1 Domain (SPRED) 1 or SPRED2 with DYRK1A Modifies Substrate/Kinase Interactions*

  2010cited by this paper
• Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.

  2010cited by this paper
• Adenovirus Type 5 E1A and E6 Proteins of Low-Risk Cutaneous Beta-Human Papillomaviruses Suppress Cell Transformation through Interaction with FOXK1/K2 Transcription Factors

  2010cited by this paper
• Function and regulation of Dyrk1A: towards understanding Down syndrome

  2009cited by this paper
• EGG-4 and EGG-5 Link Events of the Oocyte-to-Embryo Transition with Meiotic Progression in C. elegans.

  2009cited by this paper
• The zebrafish dyrk1b gene is important for endoderm formation

  2009cited by this paper
• Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A

  2009cited by this paper
• Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease

  2009cited by this paper
• Regulation of MBK-2/DYRK by CDK-1 and the pseudophosphatases EGG-4 and EGG-5 during the oocyte-to-embryo transition.

  2009cited by this paper
• Nonprimed and DYRK1A-primed GSK3β-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons

  2009cited by this paper
• DYRK1A Is a Novel Negative Regulator of Cardiomyocyte Hypertrophy*

  2009cited by this paper
• QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.

  2009cited by this paper
• Negative Feedback Inhibition of NFATc1 by DYRK1A Regulates Bone Homeostasis*

  2009cited by this paper
• Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).

  2009cited by this paper
• Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

  2009cited by this paper
• DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome.

  2008cited by this paper
• Inhibitor of DNA binding 2 is a small molecule-inducible modulator of peroxisome proliferator-activated receptor-gamma expression and adipocyte differentiation.

  2008cited by this paper
• Characterization of the human DYRK1A promoter and its regulation by the transcription factor E2F1

  2008cited by this paper
• Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly.

  2008cited by this paper
• Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome*♦

  2008cited by this paper
• The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development.

  2008cited by this paper
• The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4.

  2008cited by this paper
• The selectivity of inhibitors of protein kinase CK2: an update.

  2008cited by this paper
• DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine

  2008cited by this paper
• Chemical genetics: where genetics and pharmacology meet.

  2007cited by this paper
• The selectivity of protein kinase inhibitors: a further update.

  2007cited by this paper
• The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.

  2007cited by this paper
• DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding.

  2007cited by this paper
• Dual-specificity tyrosine phosphorylation-regulated kinase 1A does not require tyrosine phosphorylation for activity in vitro.

  2007cited by this paper
• The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression.

  2007cited by this paper
• Biotransformation of green tea polyphenols and the biological activities of those metabolites.

  2007cited by this paper
• DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage.

  2007cited by this paper
• A repressor complex, AP4 transcription factor and geminin, negatively regulates expression of target genes in nonneuronal cells

  2006cited by this paper
• Molecular and cellular targets

  2006cited by this paper
• Kinetic properties of a MNB/DYRK1A mutant suitable for the elucidation of biochemical pathways.

  2006cited by this paper
• Phosphorylation of Amphiphysin I by Minibrain Kinase/Dual-specificity Tyrosine Phosphorylation-regulated Kinase, a Kinase Implicated in Down Syndrome*

  2006cited by this paper
• NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21

  2006cited by this paper
• DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis

  2006cited by this paper
• Putative therapeutic agents for the learning and memory deficits of people with Down syndrome.

  2006cited by this paper
• Characterization of the reversible phosphorylation and activation of ERK8.

  2006cited by this paper
• Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.

  2006cited by this paper
• A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation.

  2006cited by this paper
• Identification of Yin-Yang Regulators and a Phosphorylation Consensus for Male Germ Cell-Associated Kinase (MAK)-Related Kinase

  2006cited by this paper
• Functional Consequences of Mutations in CDKL5, an X-linked Gene Involved in Infantile Spasms and Mental Retardation*

  2006cited by this paper
• HAN11 binds mDia1 and controls GLI1 transcriptional activity.

  2006cited by this paper
• Activation of a Nuclear Cdc2-Related Kinase within a Mitogen-Activated Protein Kinase-Like TDY Motif by Autophosphorylation and Cyclin-Dependent Protein Kinase-Activating Kinase

  2005cited by this paper
• Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs.

  2005cited by this paper
• Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.

  2005cited by this paper
• Regulation of protein kinases; controlling activity through activation segment conformation.

  2004cited by this paper
• Phosphorylation of Ser640 in Muscle Glycogen Synthase by DYRK Family Protein Kinases*

  2004cited by this paper
• Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2α

  2004cited by this paper
• A receptor for green tea polyphenol EGCG

  2004cited by this paper
• Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks*

  2004cited by this paper
• Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event.

  2004cited by this paper
• Unusual function of the activation loop in the protein kinase DYRK1A.

  2003cited by this paper
• Structural basis for recruitment of glycogen synthase kinase 3β to the axin—APC scaffold complex

  2003cited by this paper
• Serine/Threonine Kinase Mirk/Dyrk1B Is an Inhibitor of Epithelial Cell Migration and Is Negatively Regulated by the Met Adaptor Ran-binding Protein M*

  2003cited by this paper
• The MNB/DYRK1A protein kinase: neurobiological functions and Down syndrome implications.

  2003cited by this paper
• The MNB/DYRK1A protein kinase: genetic and biochemical properties.

  2003cited by this paper
• The specificities of protein kinase inhibitors: an update.

  2003cited by this paper
• MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha.

  2002cited by this paper
• MAPKK-Independent Activation of p38α Mediated by TAB1-Dependent Autophosphorylation of p38α

  2002cited by this paper
• Regulation of Gli1 Transcriptional Activity in the Nucleus by Dyrk1*

  2002cited by this paper
• Mammalian MAP kinase signalling cascades

  2001cited by this paper
• Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A.

  2001cited by this paper
• High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth

  2001cited by this paper
• Yak1p, a DYRK family kinase, translocates to the nucleus and phosphorylates yeast Pop2p in response to a glucose signal.

  2001cited by this paper
• Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’)

  2001cited by this paper
• Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition.

  2001cited by this paper
• The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site.

  2001cited by this paper
• ERK7 Is an Autoactivated Member of the MAPK Family*

  2001cited by this paper
• Crystal Structure of Glycogen Synthase Kinase 3β: Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition

  2001cited by this paper
• Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity.

  1999cited by this paper
• Molecular cloning and characterization of a novel member of the MAP kinase superfamily

  1999cited by this paper
• Pharmacokinetics of Hoasca alkaloids in healthy humans.

  1999cited by this paper
• Inhibition of monoamine oxidase A by beta-carboline derivatives.

  1997cited by this paper
• Inhibition of Monoamine Oxidase A by β-Carboline Derivatives

  1997cited by this paper
• PEST sequences and regulation by proteolysis.

  1996cited by this paper
• Active and inactive protein kinases: structural basis for regulation.

  1996cited by this paper
• Dyrk, a Dual Specificity Protein Kinase with Unique Structural Features Whose Activity Is Dependent on Tyrosine Residues between Subdomains VII and VIII (*)

  1996cited by this paper
• A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region.

  1996cited by this paper
• minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila.

  1995cited by this paper
• Modulation of the glycogen synthase kinase‐3 family by tyrosine phosphorylation.

  1993cited by this paper
• Microtubule-associated protein 2 kinases, ERK1 and ERK2, undergo autophosphorylation on both tyrosine and threonine residues: implications for their mechanism of activation.

  1991cited by this paper
• Mouse Erk-1 gene product is a serine/threonine protein kinase that has the potential to phosphorylate tyrosine.

  1991cited by this paper

• Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation

  2026cites this paper
• Discovery of Dietary Plant Flavonols as Novel Potent Inhibitors Targeting DYRK1A Kinase

  2025cites this paper
• DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes

  2025cites this paper
• The role of Goldilocks protein kinase DYRK1A in embryonic development.

  2025cites this paper
• A Comprehensive Investigation on the Role of Bioactives on DYRK1A to Avert Alzheimer’s Disease

  2025cites this paper
• Critical role of the CMGC insert sequence for tyrosine autophosphorylation in the protein kinase DYRK1B

  2025cites this paper
• DYRK1A in the physiology and pathology of the neuron-astrocyte axis

  2025cites this paper
• Effects of maternal drinking patterns and epigallocatechin-3-gallate treatment on behavioural and molecular outcomes in a mouse model of fetal alcohol spectrum disorders.

  2025cites this paper
• Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome

  2025cites this paper
• Unlocking the Therapeutic Potential of the Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitors in Alzheimer’s Diseases

  2025cites this paper
• Novel small-molecule inhibitors of the protein kinase DYRK: Potential therapeutic candidates in cancer

  2025cites this paper
• Application of a macrocyclization strategy in kinase inhibitor development

  2025cites this paper
• Unveiling the biophysical basis of DYRK kinase family isoform selectivity mechanism of Abemaciclib using computational approaches

  2025cites this paper
• Biology and pharmacological inhibition of homeodomain-interacting protein kinases

  2025cites this paper
• Structural perspective on the design of selective DYRK1B inhibitors

  2025cites this paper
• Regulatory mechanisms governing GLI proteins in hedgehog signaling

  2024cites this paper
• Unveiling the Therapeutic Potential of Folate-Dependent One-Carbon Metabolism in Cancer and Neurodegeneration

  2024cites this paper
• Connecting GSK-3β Inhibitory Activity with IKK-β or ROCK-1 Inhibition to Target Tau Aggregation and Neuroinflammation in Alzheimer’s Disease—Discovery, In Vitro and In Cellulo Activity of Thiazole-Based Inhibitors

  2024cites this paper
• Therapeutic approaches in proteinopathies.

  2024cites this paper
• Exploring Novel GSK-3β Inhibitors for Anti-Neuroinflammatory and Neuroprotective Effects: Synthesis, Crystallography, Computational Analysis, and Biological Evaluation

  2024cites this paper
• Analysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR

  2024cites this paper
• Protein Kinases and their Inhibitors Implications in Modulating Disease Progression

  2023cites this paper
• DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner

  2023cites this paper
• Understanding the genetic mechanisms and cognitive impairments in Down syndrome: towards a holistic approach

  2023cites this paper
• Identification of FAM53C as a suppressive binding protein of a neurodevelopmental disorders-related kinase DYRK1A

  2023cites this paper
• The potential of psychedelics for the treatment of Alzheimer's disease and related dementias.

  2023cites this paper
• Function and Inhibition of DYRK1A: emerging roles of treating multiple human diseases.

  2023cites this paper
• Identification of FAM53C as a cytosolic-anchoring inhibitory binding protein of the kinase DYRK1A

  2023cites this paper
• Hsc70 phosphorylation patterns and calmodulin regulate AP2 CCV life span for cell adhesion protein transport.

  2023cites this paper
• Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice

  2023cites this paper
• Imidazo[4,5-b]pyridines: from kinase inhibitors to more diversified biological properties.

  2023cites this paper
• The Omnipresence of DYRK1A in Human Diseases

  2022cites this paper
• Kinase-independent activity of DYRK1A promotes viral entry of highly pathogenic human coronaviruses

  2022cites this paper
• DYRK2 maintains genome stability via neddylation of cullins in response to DNA damage.

  2022cites this paper
• A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing.

  2022cites this paper
• DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD

  2022cites this paper
• Screening of a Halogen-Enriched Fragment Library Leads to Unconventional Binding Modes.

  2022cites this paper
• Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome

  2022cites this paper
• In-silico study for African plants with possible beta-cell regeneration effect through inhibition of DYRK1A

  2022cites this paper
• Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core

  2022cites this paper
• Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B

  2022cites this paper
• Harmine suppresses collagen production in hepatic stellate cells by inhibiting DYRK1B.

  2022cites this paper
• Expression and purification of DYRK1A kinase domain in complex with its folding intermediate-selective inhibitor FINDY.

  2022cites this paper
• Impaired macroglial development and axonal conductivity contributes to the neuropathology of DYRK1A-related intellectual disability syndrome

  2022cites this paper
• Type 2 Diabetes Mellitus and Alzheimer’s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets

  2022cites this paper
• Rational Design and Identification of Harmine‐Inspired, N‐Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System **

  2022cites this paper
• Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.

  2022cites this paper
• Identification of Pharmacophoric Fragments of DYRK1A Inhibitors Using Machine Learning Classification Models

  2022cites this paper
• A natural compound harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway.

  2021cites this paper
• Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.

  2021cites this paper
• Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.

  2021cites this paper
• The CDC37‐HSP90 chaperone complex co‐translationally degrades the nascent kinase‐dead mutant of HIPK2

  2021cites this paper
• K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR

  2021cites this paper
• Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling.

  2021cites this paper
• Interplay Between CMGC Kinases Targeting SR Proteins and Viral Replication: Splicing and Beyond

  2021cites this paper
• DYRK1A role in microtubule-based axonal transport regulates the retrograde dynamics of APP vesicles in human neurons

  2021cites this paper
• Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts

  2021cites this paper
• Alkaloids of Peganum harmala L. and their Pharmacological Activity

  2021cites this paper
• Current status and future prospects of molecular hybrids with thiazolidinedione (TZD) scaffold in anticancer drug discovery.

  2021cites this paper
• Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A.

  2021cites this paper
• Proteomic changes induced by harmine in human brain organoids reveal signaling pathways related to neuroprotection

  2021cites this paper
• Diabetic Kinome Inhibitors—A New Opportunity for β-Cells Restoration

  2021cites this paper
• Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry

  2021cites this paper
• DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis

  2021cites this paper
• Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview

  2021cites this paper
• Structure–Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation

  2020cites this paper
• Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins

  2020cites this paper
• Synthesis and Biological Validation of a Harmine-based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

  2020cites this paper
• The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis

  2020cites this paper
• How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition—The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine

  2020cites this paper
• Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.

  2020cites this paper
• In silico modeling studies of N9 -substituted harmine derivatives as potential anticancer agents: combination of ligand-based and structure-based approaches

  2020cites this paper
• Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.

  2020cites this paper
• Traditional Use of Banisteriopsis caapi Alone and Its Application in a Context of Drug Addiction Therapy

  2020cites this paper
• Mining Public Domain Data to Develop Selective DYRK1A Inhibitors.

  2020cites this paper
• Expression of protein kinase HIPK2 is subject to a quality control mechanism that acts during translation and requires its kinase activity to prevent degradation of nascent HIPK2.

  2020cites this paper
• Molecular mechanisms involved in the cerebral cortex development and their implications in neurodevelopmental disorders

  2019cites this paper
• Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice

  2019cites this paper
• Natural harmine negatively regulates the developmental signaling network of Drosophila melanogaster (Drosophilidae: Diptera) in vivo.

  2019cites this paper
• Regulation of folate and methionine metabolism by multisite phosphorylation of human methylenetetrahydrofolate reductase

  2019cites this paper
• A TOR-YAK1 signaling axis controls cell cycle, meristem activity and plant growth in Arabidopsis

  2019cites this paper
• Dual-specificity tyrosine phosphorylation-regulated kinase 1A ameliorates insulin resistance in neurons by up-regulating IRS-1 expression

  2019cites this paper
• The 6π-azaelectrocyclization of azatrienes. Synthetic applications in natural products, bioactive heterocycles, and related fields.

  2019cites this paper
• An ELISA DYRK 1 A non-radioactive assay suitable for the characterization of inhibitors

  2019cites this paper
• Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome.

  2019cites this paper
• Pharmacologic and genetic approaches define human pancreatic beta cell mitogenic targets of DYRK1A inhibitors.

  2019cites this paper
• The NRON complex controls circadian clock function through regulated PER and CRY nuclear translocation

  2019cites this paper
• Title Selective inhibition of the kinase DYRK 1 A by targeting itsfolding process

  2019cites this paper
• Computational Modelling of Kinase Inhibitors as Anti-Alzheimer Agents

  2018cites this paper
• Mechanisms of B-Myb oncogenicity in ovarian cancer

  2018cites this paper
• A wake‐up call to quiescent cancer cells – potential use of DYRK1B inhibitors in cancer therapy

  2018cites this paper
• DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169

  2018cites this paper
• The Role of p130/DREAM in Silencing Self-renewal Genes in Post-mitotic Neurons.

  2018cites this paper
• DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B

  2018cites this paper
• A High-Throughput Screen Identifies DYRK1A Inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation.

  2018cites this paper
• DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives

  2018cites this paper
• DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome

  2018cites this paper
• DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.

  2018cites this paper
• The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb

  2018cites this paper
• Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

  2018cites this paper